Volume: 26 Issue: 6
Michel G Bergeron ?MGB? ? a true success
Digging for new solutions
Invasive disease due to Haemophilus influenzae type A in children in Canada?s north: A priority for prevention.
Letter to the Editor: Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients
An unusual case of abdominal pain
Characterization of invasive Neisseria meningitidis from Atlantic Canada, 2009 to 2013: With special reference to the nonpolysaccharide vaccine targets (PorA, factor H binding protein, Neisseria heparin-binding antigen and Neisseria adhesin A)<span style="font-style: italic">Neisseria meningitidis</span> can cause several invasive diseases. Serogroup distribution has been known to be related to geographical differences and, in Canada, most invasive meningococcal disease cases have been caused by serogroups B (MenB) and C. Following the introduction of a meningitis C vaccine, most cases are now caused by MenB. Characterization of invasive meningococcal disease case isolates from Atlantic Canada provides a snap shot of the molecular epidemiology, shedding light on the future of a MenB vaccine.
Fidaxomicin: A novel agent for the treatment of Clostridium difficile infectionOral vancomycin and oral metronidazole have several limitations with regard to their use in the treatment of <span style="font-style: italic">Clostridium difficile </span>infections (CDIs); howeve...
Source: Canadian Journal of Infectious Diseases and Medical Microbiology - Category: Infectious Diseases Source Type: research
More News: Chemistry | Children | Clinical Trials | Clostridium Difficile | Education | Enterococcus | Epidemiology | Gastroenterology | Haemophilus Influenzae (Hib) | Health | Hepatitis | Hepatitis C | Hepatitis Vaccine | HIV-Leishmania Co-infection | Incivek | Infectious Diseases | Influenza Vaccine | Laboratory Medicine | Men | Meningitis | Meningitis Vaccine | Metronidazole | Microbiology | Pain | Vaccines